What Changed
Price Move History
- Daily moves over 5%
- 66 252 sessions, November 20, 2025 to November 20, 2026
- Largest daily move
- -39.2% close of October 22, 2026
- 1-year change
- -61.9% closing prices, November 20, 2025 to November 20, 2026
- 1-month change
- -45.3% closing prices, October 20, 2026 to November 20, 2026
Company Description
Avalo Therapeutics, Inc. (NASDAQ: AVTX) is a clinical stage biotechnology company focused on the treatment of immune dysregulation and immune-mediated inflammatory diseases. According to the company’s public statements, Avalo is fully dedicated to developing IL‑1β‑based treatments for these conditions, with its work centered on targeted monoclonal antibody therapies.
Avalo’s business is built around the research, development and clinical testing of biologic drug candidates. The company’s lead asset is AVTX‑009, described as a humanized monoclonal antibody (IgG4) that binds to interleukin‑1β (IL‑1β) with high affinity and neutralizes its activity. IL‑1β is characterized in Avalo’s materials as a pro‑inflammatory cytokine that plays a central role in the pathogenesis of a wide range of human diseases and is a major, validated target for therapeutic intervention. Dysregulated IL‑1β signaling is cited as a major driver of inflammation and the progression of autoimmune and other inflammatory disorders.
Clinical focus and lead program
The company reports that AVTX‑009 is in a Phase 2 clinical trial for hidradenitis suppurativa (HS), referred to as the LOTUS trial. HS is described in Avalo’s disclosures as a chronic, progressive, often debilitating inflammatory skin disease that causes painful nodules, abscesses and tunnels to form under the skin. The disease is associated with chronic inflammation that can lead to tissue destruction and permanent scarring if not adequately treated. Avalo highlights HS as a condition with significant remaining unmet medical need.
The LOTUS trial is described as a randomized, double‑blind, placebo‑controlled, parallel‑group Phase 2 study in adults with moderate to severe HS. Subjects are randomized to receive one of two AVTX‑009 dosing regimens or placebo over a 16‑week treatment phase. The primary efficacy endpoint disclosed by the company is the proportion of subjects achieving Hidradenitis Suppurativa Clinical Response at the 75% level (HiSCR75) at Week 16. Secondary objectives include the proportion of patients achieving HiSCR50 and HiSCR90, and changes from baseline in several HS disease activity measures and patient‑reported skin pain assessments.
Scientific and therapeutic rationale
In its public descriptions, Avalo emphasizes the central role of IL‑1β in inflammation. IL‑1β is said to activate immune cells that generate additional pro‑inflammatory cytokines, including IL‑6, TNF‑α and IL‑17. The company notes that IL‑1β overproduction or dysregulation is implicated in many autoimmune and inflammatory diseases, and that IL‑1β inhibition has proven effective in multiple immune‑mediated inflammatory diseases. This scientific rationale underpins Avalo’s focus on IL‑1β‑targeted therapies and the development of AVTX‑009.
Avalo’s disclosures also reference broader potential for IL‑1β inhibition beyond HS. The company notes evidence that IL‑1β inhibition could be effective in hidradenitis suppurativa and a variety of inflammatory diseases in dermatology, gastroenterology and rheumatology, and that it is exploring additional opportunities in prevalent indications with significant unmet needs. These statements frame Avalo’s strategy as concentrating on immune dysregulation and inflammatory pathways where IL‑1β is a key driver.
Pipeline and development orientation
Public materials indicate that Avalo is a clinical‑stage organization, with its efforts focused on advancing AVTX‑009 through clinical development. Earlier descriptions of the company’s pipeline reference additional assets, including quisovalimab (an anti‑LIGHT monoclonal antibody) and AVTX‑008 (a BTLA agonist fusion protein), but current company communications consistently highlight AVTX‑009 as the lead asset and central development priority.
The company’s reported activities include conducting global clinical trials, preparing for data readouts, and planning for potential later‑stage development. Avalo also reports efforts to expand its leadership team and board of directors with individuals experienced in clinical development, regulatory strategy, business development and capital markets, reflecting a focus on executing its development plans and corporate strategy around immune‑mediated inflammatory diseases.
Regulatory and public company status
Avalo Therapeutics, Inc. is incorporated in Delaware and files reports with the U.S. Securities and Exchange Commission under Commission File Number 001‑37590. The company’s common stock trades on The Nasdaq Capital Market under the ticker symbol AVTX. Recent Form 8‑K filings describe events such as financial results announcements, updates to investor presentations, and appointments of directors and senior executives, illustrating the company’s status as an actively reporting public issuer.
Through these filings and press releases, Avalo presents itself as a biotechnology company in the pharmaceutical preparation manufacturing sector, with a specialized focus on IL‑1β‑targeted biologics for immune‑mediated inflammatory diseases. Investors and observers looking at AVTX stock are primarily evaluating the progress, safety and efficacy data of AVTX‑009 in hidradenitis suppurativa and the broader potential of IL‑1β‑based approaches in immune dysregulation.
Position within the biotechnology landscape
Within the broader biotechnology and pharmaceutical preparation manufacturing sector, Avalo’s niche is defined by its concentration on immune dysregulation and IL‑1β biology. Rather than a broad portfolio across many mechanisms, the company’s public communications emphasize a focused approach on IL‑1β‑based treatments and on immune‑mediated inflammatory diseases where this pathway is believed to be central. This specialization shapes its clinical trial design, scientific rationale and investor communications.
For market participants researching AVTX stock, key themes in Avalo’s disclosures include the mechanism of action of AVTX‑009, the design and endpoints of the LOTUS Phase 2 trial in HS, the scientific justification for targeting IL‑1β in immune‑mediated inflammatory diseases, and the company’s intention to explore additional indications where IL‑1β‑driven inflammation plays a significant role.
Key points for AVTX investors
- A clinical stage biotechnology company focused on immune dysregulation and immune‑mediated inflammatory diseases.
- Lead asset AVTX‑009, a humanized monoclonal antibody targeting IL‑1β, in Phase 2 development for hidradenitis suppurativa.
- Strategic emphasis on IL‑1β as a central driver of inflammation and a validated therapeutic target.
- Public company listed on The Nasdaq Capital Market under the symbol AVTX, incorporated in Delaware.
- Ongoing clinical and corporate updates communicated through press releases and SEC filings, including Form 8‑K reports.
Stock Performance
Avalo Therapeutics (AVTX) closed at $6.76 on November 20, 2026. Over the past 12 months, the price has lost 61.9%.
AVTX Metrics & Rankings
Price returns through November 20, 2026. Month and year figures include the first trading day. Ranking links may use different dates.
Latest News
Avalo Therapeutics has 10 recent news articles, with the latest published on . Of the recent coverage, 1 article coincided with positive price movement and 8 with negative movement. Key topics include earnings, conferences. View all AVTX news →
SEC Filings
Avalo Therapeutics has filed 10 recent SEC filings, including 4 Form SCHEDULE 13G/A, 2 Form SCHEDULE 13G, 2 Form 8-K, 1 Form S-3ASR. The most recent filing was submitted on . SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all AVTX SEC filings →
Insider Radar
Insider selling at Avalo Therapeutics over the past 90 days can reflect routine portfolio management, scheduled trading plans (Rule 10b5-1), tax planning, or compensation-related dispositions rather than a directional view on the stock.
Financial Highlights
Avalo Therapeutics generated $59K in revenue in FY2025, operating income reached -$72.9M, and net income was -$78.3M. Diluted earnings per share stood at -$5.84. The company generated -$51.5M in operating cash flow. The current ratio was 8.14, measuring current assets divided by current liabilities.
Upcoming Events
Abdakibart Phase 3 Start
AVTX-010 IND Submission
IND submission planned
Phase 3 program start
AVTX-010 IND filing
25% option vesting cliff
Employee option vesting
Remaining options fully vested
Avalo Therapeutics has 8 upcoming scheduled events. The next event, "Abdakibart Phase 3 Start", is expected in H1 2027. Investors can track these dates to stay informed about potential catalysts that may affect the AVTX stock price.
Short Interest History
Short interest in Avalo Therapeutics (AVTX) currently stands at 8.9 million shares, down 25.5% from the previous reporting period, representing 15.7% of the float. Since November 2025, short interest has increased by 382.1%.
Days to Cover History
Days to cover for Avalo Therapeutics (AVTX) currently stands at 2.1 days, down 83.9% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 60%. Across the settlements charted above, it has ranged from 1.6 to 20.2 days.
AVTX Company Profile & Sector Positioning
Avalo Therapeutics (AVTX) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.
Investors comparing AVTX often look at related companies in the same sector, including Shattuck Labs, Inc. (STTK), Assembly Biosciences, Inc (ASMB), Gyre Therapeutics, Inc. (GYRE), Arvinas, Inc (ARVN), and CytomX Therapeutics, Inc. (CTMX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate AVTX's relative position within its industry.